CooperCompanies Stock - analyst consensus and sector context into the week

CooperCompanies stock trades steadily after recent earnings, with Wall Street estimates broadly unchanged and the medical devices peer group setting the tone. A look at current consensus numbers, sector backdrop and where the stock stands now.

Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 16:33 CET. Details in the imprint.

CooperCompanies (US21664P1039) remains a steady mid-cap name in the US medical devices space. Recent quarterly numbers and guidance left Wall Street estimates broadly intact, according to current analyst overviews.

What the current estimates show

According to a current overview on MarketBeat, analysts expect CooperCompanies to generate earnings per share of roughly $4.62 in its current fiscal period, with management guiding a range around this level in recent communications.

The same compilation shows revenue expectations at around $4.3 billion for the period, again closely aligned with the company’s own guidance corridor of about $4.3 billion. That tight range underlines relatively clear visibility in CooperCompanies’ core businesses.

How peers frame the sector backdrop

CooperCompanies operates alongside names such as Alcon, Bausch + Lomb and Johnson & Johnson’s vision-care unit in the global eye-care and medical devices market. Demand for contact lenses and women’s health solutions tends to be less cyclical than for many discretionary products.

At the same time, the sector is sensitive to procedure volumes and reimbursement decisions, which investors monitor across the peer group via quarterly updates. Against this backdrop, valuation spreads within medical technology remain meaningful, reflecting differing growth and margin profiles.

How analysts view the stock today

Consensus data compiled by MarketBeat indicate that most covering analysts rate CooperCompanies at neutral to positive, with a mix of Hold and Buy recommendations and only isolated more cautious views. Price targets cluster not far from prevailing trading levels.

This distribution points to a broadly balanced risk-reward assessment at present. Upside cases typically hinge on sustained growth in premium silicone hydrogel lenses and further margin improvements, while downside scenarios focus on competition and pricing pressure.

The business behind CooperCompanies

CooperCompanies generates the bulk of its revenue through CooperVision, which develops and sells soft contact lenses, including daily disposable and toric lenses for astigmatism. Its CooperSurgical unit adds a portfolio of fertility, obstetrics and gynecology products for women’s health.

Where the stock trades today

CooperCompanies stock (US21664P1039) trades on the Nasdaq at $65.91 as of 06/18/2026, 16:00 Eastern Time.

Key facts on CooperCompanies stock

• Company: The Cooper Companies Inc.
• ISIN: US21664P1039
• WKN: 859572
• Ticker: COO
• Venue: Nasdaq
• Price (as of 06/18/2026, 16:00 Eastern Time): 65.91 USD
• Market cap: 6.90 billion USD (as of 06/18/2026)
• Sector / Industry: Health Care - Medical Devices
• Index membership: S&P 500
• Next earnings date: not officially scheduled

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.